Targeting PD-L1 and TIGIT in Tumors With Tertiary Lymphoid Structures

Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Study ID
NCT06713798
Phase
PHASE2
Status
Withdrawn

Conditions

  • Advanced Lung Cancer
  • CBNPC Cancer
  • Metastatic Cancer Lung

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Atezolizumab 1200 mg IV — DRUG
    atezolizumab (intravenous 1200mg Q3W)
  • Tiragolumab 600 mg IV — DRUG
    Tiragolumab (intravenous 600mg Q3W)

Study Details

This study encompasses multicenter open-label, phase II trials. Patients will be dispatched into 2 cohorts: * Cohort A: Patients naïve from systemic treatment will be randomized according to two treatment modalities: atezolizumab + tiragolumab (arm A1) versus atezolizumab monotherapy (arm A2). 43 patients are to be included in each arm. * Cohort B: Patients with previous exposure to ICI will be treated with the combination of atezolizumab and tiragolumab. 29 patients are to be included in this cohort.

Key Dates

Start date
Jan 30, 2025
Status verified
Mar 2026
Primary completion
Sep 15, 2025
Completion
Sep 15, 2025

Study Design

Enrollment
0 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: A1 : the patients naïve from systemic treatment - atezolizumab + tiragolumab
  • Experimental: A2 : the patients naïve from systemic treatment - atezolizumab
  • Experimental: B: patients with previous exposure to ICI - atezolizumab + tiragolumab

Primary Outcome Measure

Best overall response (BOR) rate [ Time Frame: after 6 months of treatment initiation ]

Related Studies